GE HealthCare (Nasdaq: GEHC) and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (Nasdaq: AMZN), today announced a strategic collaboration to develop purpose-built foundation models and generative artificial intelligence (AI) applications designed to help clinicians improve medical diagnostics and patient care. GE HealthCare has selected AWS as its strategic cloud provider and plans to use its healthcare and generative AI services to build and implement new, versatile foundation models to transform the future of healthcare. These new generative AI-powered workflows are intended to fast-track the delivery of innovations to streamline healthcare operations, increase diagnostic and screening accuracy, enhance outcomes, lower access hurdles, and promote equitable care, thereby easing provider workload and accelerating industry innovation.

“GE HealthCare has been pioneering medical technology for more than a century. With more than one billion patients around the world touched by our products, we play an important part in improving the quality of care and have a responsibility to continue pushing the boundaries of what’s possible to enable precision care,” said Peter Arduini, President and CEO, GE HealthCare. “This new collaboration with AWS allows us to build on our legacy of innovation by embracing the power of AI to expedite the creation of medical technologies that we expect will redefine clinical workflows and the delivery of care.”

GE HealthCare intends to utilize Amazon Bedrock, a fully managed service that provides secure access to the industry’s leading foundation models, to create and deploy bespoke generative AI applications, amplifying the advantages of generative AI for their customers. Leveraging Bedrock’s enterprise-grade security and privacy along with a broad selection of industry-leading foundation models, GE HealthCare plans to build and scale its own proprietary generative AI applications for healthcare use cases with an aim to enhance efficiency, care delivery, and the patient experience.

“With AWS, GE HealthCare plans to use the cloud to deliver more personalized, intelligent, and efficient care,” said Matt Garman, CEO of AWS. “GE HealthCare is putting generative AI at the heart of their innovation, accelerated by the investments we have made in healthcare-specific cloud services and generative AI capabilities that provide best-in-class security, data privacy, and access to the latest state-of-the-art foundation models. With AWS as their strategic cloud provider, GE HealthCare can build transformative clinical foundation models and applications for the healthcare industry.”

GE HealthCare’s internal developers are planning to use Amazon Q Developer, a generative AI–powered assistant to accelerate software development by generating real-time code suggestions, securely completing tasks, and more. The company also expects to use Amazon Q Business to explore the intersection of multi-modal clinical and operational data with an aim of reducing the cognitive burden on physicians, enabling personalized care, and increasing efficiency. Leveraging AWS’s generative AI technology, GE HealthCare expects to reduce clinical application development cycles from years to months and to accelerate the delivery of new healthcare solutions.

“By combining generative AI with our deep expertise, we’re igniting a new era in healthcare,” said. Dr. Taha Kass-Hout, Global Chief Science and Technology Officer at GE HealthCare. “Our work with AWS is a big step towards helping clinicians make medical care simpler, more efficient, and deeply personalized. It’s about advancing the way we care for people everywhere, one innovative solution at a time.”

Additionally, GE HealthCare plans to modernize its suite of applications with its own foundation models developed on Amazon SageMaker, a fully managed service to build, train, and deploy machine learning (ML) models. By developing its own foundation models specialized for medical use cases, GE HealthCare intends to accelerate the development and deployment of web-based medical imaging applications and integrating these foundation models to drive efficiency, interoperability, and improve user experiences across the company’s equipment and software solutions. Customers could use GE HealthCare’s generative AI-powered applications, that will integrate with AWS HealthLake and AWS HealthImaging, to quickly and securely analyze various types of patient data, leading to improved clinical efficiency and better patient care.

“We are optimistic about the ways in which generative AI will be able to transform healthcare for the better, and we look forward to seeing the new tools and applications that result from collaborations across industry and health care,” said Dr. Keith Dreyer, Chief Data Science Officer, Mass General Brigham and leader of the Mass General Brigham AI business. “As healthcare systems like Mass General Brigham lean into AI to accelerate their work, we see great potential for new foundation models that utilize advanced technologies.”

The healthcare sector is responsible for about 30%¹ of the world’s data generation, however, 97%² of this data goes largely untapped due to its unstructured nature. This collaboration will focus on the development of multi-modal foundation models designed to analyze a vast array of unstructured medical data (e.g., records, reports, and images) and provide precise, adaptable insights for a multitude of healthcare applications. Unlike traditional ML, these models can be built to interpret data across various diseases and tasks simultaneously.

GE HealthCare has been investing in AI for years. For the third year in a row, GE HealthCare topped a U.S. Food and Drug Administration (FDA) list of AI-enabled device authorizations, with 72.³ Its recent foundation model work includes a project focused on an advanced ultrasound image segmentation tool. Utilizing foundation model technology, this research tool has demonstrated great proficiency in isolating and identifying anatomical structures with over 90% accuracy, requiring little human input.⁴ Its key feature is its generalization capability, which can segment anatomical structures, including fetal heads and breast lesions, which were not part of the foundation model’s initial training set. This advanced feature demonstrates the model’s ability to be applied to uses cases beyond what it was originally trained for.

To learn more about GE HealthCare’s digital solutions and healthcare transformation, visit here.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post GE HealthCare and AWS Announce Strategic Collaboration first appeared on AI-Tech Park.

Through the synergy of ZayaAI’s state-of-the-art technology and Enjinstarter’s expertise in Web3 solutions, both companies aspire to enhance the precision and efficiency of pathology diagnostics, setting new standards in healthcare innovation.

The partnership includes a strategic Initial DEX Offering (IDO) hosted by Enjinstarter, aimed at accelerating the development and deployment of ZayaAI’s cutting-edge diagnostic solutions. This IDO, set to launch September 2024, will provide crucial funding to expand ZayaAI’s reach and impact in the healthcare industry. Early investors will have the opportunity to support ZayaAI’s mission and be part of a transformative journey in medical diagnostics.

Cristian Mogodici, CEO of ZayaAI, expressed his enthusiasm for the partnership: “We are thrilled to join forces with Enjinstarter. Their expertise in Web3 crowdfunding and blockchain technology perfectly complements our vision of driving innovation in healthcare through advanced digital solutions.”

This partnership will leverage Enjinstarter’s robust platform to enhance ZayaAI’s diagnostic solutions, ensuring data integrity and fostering innovation in pathology and beyond. The collaboration will drive the development and deployment of advanced AI tools, bringing transformative changes to the healthcare industry.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post ZayaAI announced partnership with Enjinstarter first appeared on AI-Tech Park.

The Hospital will use SOPHiA DDM to enhance its testing and research of blood cancers

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that Kepler Uniklinikum, Austria’s second largest hospital, is live on SOPHiA GENETICS’ platform. The hospital will use the SOPHiA DDM Platform to advance its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers.

Kepler Uniklinikum, which has 1,800 beds, is the central healthcare provider for Upper Austria. The hospital will implement the SOPHiA DDM Platform across its medical and chemical laboratory locations to deepen its in-house NGS testing capabilities and expand its offerings to its patients, specifically for those faced with blood cancers and disorders.

Cancer is the second most common cause of death in Austria, with about 42,000 people diagnosed with cancer each year.¹ Additionally, on a global scale, blood cancers are the fifth most common type of cancer in the world.² Advances in diagnostics and treatment of blood cancers depend on timely, cost-effective, and reliable sequencing data. The SOPHiA DDM Platform uses NGS to target key variants from FFPE, blood, or bone marrow samples, helping lead to fast and accurate detection of variants associated with the disease. The SOPHiA DDM Platform is specifically designed to compute a wide array of genomic variants and continually hones its machine learning algorithms to detect genomic variants associated with rare and challenging cases.

“Kepler Uniklinikum’s implementation of the SOPHiA DDM Platform will help progress the use of data-driven medicine throughout Austria by ensuring their patients receive the most advanced and accurate testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “This testing will not only help the local population but will provide valuable insights and data to support others using the SOPHiA DDM Platform around the world.”

The SOPHiA DDM Platform delivers results that are nearly 100 percent reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Kepler Uniklinikum Joins SOPHiA DDM™ Platform first appeared on AI-Tech Park.

The Agilent 7010D Triple Quadrupole GC/MS System (7010D GC/TQ) features the new HES 2.0 ion source, providing attogram-level sensitivity, unmatched robustness, and industry-leading uptime. Built-in intelligence, including SWARM autotune and Early Maintenance Feedback (EMF), streamlines analytical workflows and reduces unplanned instrument downtime, making it a reliable partner in navigating evolving regulatory requirements.

The 7010D GC/TQ also includes the My Green Lab Accountability, Consistency, and Transparency (ACT) Label, reflecting environmentally conscious manufacturing practices. Additionally, the MassHunter Acquisition 13.0 software enhances user experience with a refreshed interface and compliance tools, enabling users to take control of data integrity and adhere to compliance guidelines such as FDA 21 CFR Part 11, EU Annex 11, and GAMP5.

The Agilent ExD Cell available for the 6545XT AdvanceBio LC/Q-TOF enhances peptide and protein characterization capabilities by adding electron capture dissociation (ECD). With the trend towards increasingly complex biotherapeutics this meets the need for more thorough structural characterization.

The field installable ExD cell addon for the 6545XT is designed for researchers in the ‘discovery phase’ who are faced with diverse analytical challenges. ECD is particularly appropriate for the study of large proteins, fragile modifications, and isomeric residues – analytes which can be difficult to unambiguously characterize with traditional collision induced dissociation (CID) methods alone.

Coupled with the inherent capabilities of the 6545XT for intact protein analyses, the ExD cell is also suited for performing top to middle down characterization of large and highly charged proteins (such as antibodies) and smaller subunits (such as peptides), and the rich spectra produced can be interpreted with confidence using the ExDViewer.

“Intelligence capabilities are seamlessly integrated into instruments like the 7010D GC/TQ, recognizing the fiercely competitive landscape that is constantly evolving. Additionally, the Agilent ExD cell, in conjunction with the 6545XT AdvanceBio LC/Q-TOF, empowers scientists to meticulously scrutinize and more effectively characterize peptides—critical components in modern research and therapeutics,” stated Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division.

“These cutting-edge products exemplify customer-driven innovation and excellence. By listening to our customers, we gain valuable insights into their challenges. We then channel this understanding into consistent innovation, resulting in outstanding products that precisely meet their needs,” added Suzuki.

Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Agilent Announces Cutting-Edge Advances in Technology at ASMS 2024 first appeared on AI-Tech Park.

EGFR is a biomarker that presents in some patients with NSCLC and that has specific targeted therapies associated with it. Currently, ~30-40% of eligible NSCLC patients do not receive appropriate testing¹. In September 2023, Tempus and AstraZeneca initiated a pilot program to leverage Next to identify this specific care gap at participating provider sites, using AI to scan unstructured clinical data to understand which patients may be eligible for testing based on clinical guidelines, and notifying treating physicians to inform care. The pilot’s initial success within the first six months prompted a new expansion of the program to support deployment of the care pathway model in a total of 15 provider sites.

“Next was designed to ensure all patients have access to treatment plans based on the most up-to-date guidelines by equipping physicians with cutting-edge tools in their existing workflows to support the delivery of evidence-based care,” said Chris Scotto DiVetta, Senior Vice President, AI Applications at Tempus. “We were excited to see initial success in this program and look forward to contributing to a future where advanced technology and medical expertise unite to improve outcomes for all patients.”

Tempus Next is designed to accelerate the adoption of precision medicine and enhance patient outcomes. The solution integrates seamlessly with EMRs in order to analyze a comprehensive suite of data—including clinical notes, molecular information, and imaging—to pinpoint certain deviations from care guidelines. Participating health systems receive regular updates, supporting guideline-directed care for their patients. To learn more, visit tempus.com/oncology/care-pathway-solution.

¹ Sadik H, Pritchard D, Keeling DM, et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022;6:e2200246. doi:10.1200/PO.22.00246

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Tempus Announces Expansion of Collaboration with AstraZeneca first appeared on AI-Tech Park.

To further the fight against global lung cancer, Qure.ai, a world leader in healthcare Artificial Intelligence (AI), will unveil its AI-powered lung cancer continuum at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, from May 31 to June 4, 2024.

Featuring AI solutions to identify, measure, manage, and monitor the end-to-end care, continuum is designed to support clinicians and advance developments for lung health in the pharmaceutical and medical device industries.

“Lung cancer is the leading cause of cancer-deaths worldwide, with approximately 75% of patients detected in late-stage disease. Earlier detection reduces the need for therapeutic or surgical intervention and boosts survival rates, by over 90% if treatment starts at stage 1,” states Prashant Warier, CEO and Co-founder of Qure.ai.

“Artificial intelligence for lung cancer powers early detection—not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general healthcare imaging procedures. This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates,” Prashant Warier adds.

The Qure.ai lung cancer continuum provides regulatory-cleared* individual or end-to-end detection, analysis, and monitoring tools, putting improved patient care at the heart of innovation:

• AI to identify missed lung nodules from chest X-rays and support in early lung cancer diagnosis;
• AI to measure lung nodules via CT scans and track volumetric growth as part of progression monitoring;
• AI to manage lung cancer cases via multi-modality reporting, collaboration and prioritization tools;
• AI to monitor drug efficacy and disease progression in clinical trials and cancer care research.

Qure.ai has extensive real-world experience with AI deployments at over 2700 sites in more than 90 countries. It is widely trusted by global institutions with partnerships, commercial deployments and research studies underway with AstraZeneca, the UK’s National Health Service (NHS) hospitals and major teleradiology companies in UK and US. Qure.ai is headquartered in Mumbai with regional team offices in New York and London.

*Global clearances such as FDA and EU MDR CE vary across geographies.

Contact:
Georgina Wright
georgina.wright@qure.ai

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post AI-powered lung cancer care continuum unveiled at ASCO 2024 first appeared on AI-Tech Park.

SmartLinQ 

• ASCO Certified is a new certification program announced by ASCO in October 2023. Current ASCO Certified measures are now available within SmartLinQ.
• RxLinQ is a precision medicine feature in SmartLinQ that identifies patients who are potentially eligible for newly approved, molecularly targeted therapies using advanced methods that go “beyond the biomarker.”
• TriaLinQ is a SmartLinQ feature designed to simplify and reduce the burden on clinical trial staff through practice-optimized workflows, which can increase patient matching to complex clinical trial enrollment criteria through intelligent screening.

“The pace of progress in oncology is breathtaking,” said Louis Culot, General Manager of CancerLinQ. “Supporting a diverse of oncology care providers across new drug approvals, new diagnostic modalities and alternative clinical research options  – requires a learning network approach founded on clinical AI and advanced clinical informatics. At CancerLinQ, we are privileged to be working with leading oncology centers at the forefront of these innovations.”

CancerLinQ, founded by the American Society of Clinical Oncology (ASCO^®), became a ConcertAI initiative late in 2023. As part of this transition, ASCO and CancerLinQ formed a long-term cooperation agreement and commitment to continue providing quality solutions and SaaS technologies for the oncology community.

RxLinQ

CancerLinQ is introducing RxLinQ, a precision medicine enabler of SmartLinQ, identifies patients who are potentially eligible for newly approved therapies.

Benefits include:

• Reduces administrative burden of monitoring each patient to determine eligibility for new therapies 
  
• Improves outcomes by using a “Partial Match” list to indicate patients who could be eligible for a genomic test and targeted therapy
  
• Improves population health by matching to both established and newly seen patients
  
• Automates the monitoring and notification of new approvals, allowing teams to focus on other priorities 

TriaLinQ

TriaLinQ provides patient-to-trial matching within the SmartLinQ solution.  TriaLinQ streamlines the screening, study eligibility confirmation, and enrollment processes. The solution supports investigator initiated and industry sponsored trials, automates manual tasks, enhances precision of individual patient eligibility reviews, and ensure diverse patient inclusion.

Benefits include:

• A goal to increase the yield and matching of patients to trials, especially complex trials, based on automated data workflows
• Increase in patient treatment options by expanding access to clinical trials
• Minimization of labor-intensive manual pre-screening tasks to identify eligible patients

ASCO Certification

In October 2023, ASCO announced ASCO Certified, a new set of quality measures and tools that build on ASCO’s long-standing Quality Oncology Practice Initiative (QOPI^®). CancerLinQ has provided automated solutions for QOPI Certification and now, under the ASCO-CancerLinQ agreement, will develop and deploy ASCO Certified solutions. ASCO Certified not only represents a comprehensive set of measures that incorporate the latest clinical treatment quality guidance, but it is also designed to enable patient-centered practice transformation that aligns with the oncology medical home standards co-developed by ASCO and the Community Oncology Alliance (COA) in 2021. In addition, for practices employing Elsevier ClinicalPath, CancerLinQ and Elsevier have agreed to streamline the reporting and submission process, facilitating both quality measures and required pathways metrics.

Learn more about all these new initiatives at the CancerLinQ booth (#14013) at the 2024 ASCO Annual Meeting or visit cancerlinq.org.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post CancerLinQ Enables Learning Network and Precision Oncology Solutions first appeared on AI-Tech Park.

SK Telecom (NYSE:SKM, “SKT”) today announced that it officially launched its AI-based veterinary X-ray image diagnosis assistance service ‘X Caliber’ in Australia.

X Caliber is an innovative service that uses AI to analyze X-ray images of dogs/cats within around 15 seconds. Since X Caliber uses cloud to store and retrieve data, there is no need to install a separate server within the hospital. Veterinarians can examine the results of the AI-based image diagnosis on their mobile devices or PCs anywhere, anytime. The sensitivity of X Caliber stands at 86-94%: 94% for detection of 16 different abnormal patterns from abdominal X-ray images of dogs; 88% for detection of 10 different abnormal patterns from chest X-ray images of dogs; and 86% for detection of 7 different abnormalities from musculoskeletal X-ray images of dogs.

Since entering a strategic partnership with ATX Medical Solutions (“ATX”), a leading provider of medical devices in Australia, in November 2023, SKT has been working closely with ATX to prepare for the commercial launch of the service by running beta tests. With today’s official launch, X Caliber can be used by over 100 veterinary clinics in Australia.

Australia is a pet-loving country with one of the world’s highest pet ownership rates. Over two thirds of households are estimated to own a pet, with the total number of pets standing at around 29 million as of January 2024. The average number of pets per household in Australia is 1.3 dogs and 1.6 cats.

SKT and ATX will also be attending the Australian Veterinary Association (AVA) Conference 2024, one of the largest gatherings of veterinary professionals in Australia, in Melbourne from May 27-31, to introduce X Caliber to veterinarians.

Moreover, SKT announced that it signed a commercial contract with MEDIVET Pet Hospital & Clinic, Indonesia’s largest premium veterinary hospital chain, to provide X Caliber to MEDIVET’s hospital. The company sees this deal as a good opportunity to introduce X Caliber not only to Indonesia, but also to the rest of the Southeast Asian market.

Meanwhile, SKT is currently actively providing beta service to veterinary clinics in North America, Europe, and Asia to further expand X Caliber’s presence in the global market.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post SKT Launches AI-powered Veterinary Diagnostic Assistance Service X Caliber first appeared on AI-Tech Park.

iPredict Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years. These results were peer-reviewed and accepted by the scientific review team and will be presented at the ESC Congress which will be held between 30^th August and 2^nd September 2024. The iPredict stroke and MI prediction models aim to help prevent strokes and heart attacks, saving millions of people from deaths or disabilities.

Using the high-resolution retinal color images of the individual’s eyes and health data, the iPredict AI System’s stroke and MI prediction results will be available in fully automated reports in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes.

For the identification of individuals who will suffer a stroke or heart attack in 5-year, the prediction models offer an overall accuracy of

• incident stroke with a sensitivity of 82.73%, specificity of 87.35%, and accuracy of 85.22%.
• incident MI with a sensitivity of 84.76%, specificity of 84.67%, and accuracy of 84.71%.

iPredict achieved higher accuracy than existing stroke and heart attack prediction models such as Framingham and Chads scores/CHADS2VASC scores.

iPredict’s stroke and MI models can be used to alert physicians of the need to take further preventive measures for these patients in the primary care settings.

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma which are CE certified (i.e., cleared for the European market), MHRA/UK Health, TGA/Australian and UAE health approved.

iHealthScreen company is open to partnerships for collaboration and/or co-development of its products in various territories. For more information: https://www.iHealthScreen.org

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post iHealthScreen’s Risk Prediction via Retinal Images & Health Data. first appeared on AI-Tech Park.

When asked about the collaboration, Anthony Morrison, MaximBio’s Chief Commercial Officer, said, “Their dedication to provide the best products with personal, efficient service makes them an ideal partner for MaximBio as we team up to help meet the growing demand for COVID-19 testing.” Michael Brown, Senior VP, Clinical Diagnostics at Thomas Scientific, agreed, “For over a century, Thomas Scientific has been committed to offering quality laboratory products while catering to the unique needs of the individual customer.  We are excited to add MaximBio’s innovative test to our product offering.” 

The ClearDetect^TM COVID-19 Antigen Home Test employs proven Lateral Flow Assay (LFA) technology with a simplified workflow that can easily be done at home without the need for equipment or a reader. The test’s unique format involves only 3 components—a swab, a test strip, and a test tube pre-filled with sample buffer. This eliminates reagent measuring or the need to handle dropper bottles as required with other card-based and self-test systems.

When compared to an EUA authorized PCR method, the MaximBio ClearDetect^TM COVID-19 Antigen Home Test performed well, achieving 86.9% Positive Agreement (PPA) and 98.9% Negative Agreement (NPA), making it one of the more sensitive and specific antigen tests available. The test also performed admirably when evaluated by the NIH with specimens positive for the Omicron variant, detecting 100% of live virus Omicron samples diluted to a PCR Ct value of 25.8. In the same study the assay detected the Omicron variant at a higher dilution than two other EUA-approved antigen tests.

The test will be available in two kit configurations—packaged two (2) tests in a box for convenient at-home use, and in a bulk 25-test pack amenable for healthcare settings, schools, workplaces, and other high-volume testing scenarios. Thomas Scientific will market both configurations and plans to price them competitively. MaximBio is currently ramping up production to meet the demand for COVID-19 testing and Thomas Scientific’s desire to fulfil customer needs.  

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

The post MaximBio & Thomas Scientific Ink Marketing Agreement for ClearDetectTM first appeared on AI-Tech Park.